<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227653</url>
  </required_header>
  <id_info>
    <org_study_id>EFV Kids</org_study_id>
    <nct_id>NCT03227653</nct_id>
  </id_info>
  <brief_title>Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV</brief_title>
  <official_title>Neuropsychiatric Adverse Effects of Efavirenz in Children Living With HIV in Kilimanjaro, Tanzania</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kilimanjaro Christian Medical Centre, Tanzania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kilimanjaro Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efavirenz is among the preferred antiretroviral drugs for HIV-infected children. Increasing
      evidence shows that central nervous system side-effects in adults are more common than
      previously thought. Due to lack of validated tools and small sample sizes, reliable data in
      children are lacking. As HIV-infected children nowadays have a prospect of reaching
      adulthood, there is an urgent need to identify potential long-term central nervous system
      side-effects, interfering with neurodevelopment and psychosocial maturation.

      In this cross-sectional observational study the investigators will examine neuropsychiatric
      and neurocognitive functioning in 126 children (aged 6-11 years) on long-term combination
      antiretroviral therapy (cART) with or without efavirenz.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Neuropsychological symptoms</measure>
    <time_frame>At day of inclusion</time_frame>
    <description>Neuropsychological symptoms will be assessed using the Swahili version of the Child Behavior Checklist for 6-18 years (CBCL6-18)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive functioning - non-verbal cognitive ability</measure>
    <time_frame>At day of inclusion</time_frame>
    <description>Non-verbal cognitive ability will be assessed using the Raven's Progressive Matrices</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive functioning - working memory, attention and concentration</measure>
    <time_frame>At day of inclusion</time_frame>
    <description>Working memory, attention and concentration will be assessed using the Wechsler Intelligence Scale for Children (WISC-III) Digit Span Test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment adherence</measure>
    <time_frame>At day of inclusion</time_frame>
    <description>Treatment adherence will be measured using an adherence questionnaire, adapted from the PENTA 16 trial (permission obtained from the author prof. Giaquinto)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Efavirenz</condition>
  <condition>Child Behavior</condition>
  <condition>Cognitive Symptom</condition>
  <condition>Medication Adherence</condition>
  <condition>Drug-Related Side Effects and Adverse Reactions</condition>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <description>Children using efavirenz-based cART for at least 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-efavirenz</arm_group_label>
    <description>Children using non-efavirenz-based cART for at least 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz-containing cART</intervention_name>
    <description>Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non-efavirenz containing cART</intervention_name>
    <description>Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS</description>
    <arm_group_label>Non-efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected children (6-11 years) receiving cART
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 6 until 11 years

          -  HIV seropositive

          -  Using cART, with or without efavirenz, for at least 6 months

          -  Registered patient at Kilimanjaro Christian Medical Centre or Mawenzi Regional
             Hospital

          -  In the presence of at least one parent or caregiver who is part if the child's
             life/upbringing

        Exclusion Criteria:

          -  Switch of cART regimen in the last 6 months

          -  History of birth-related brain injury, or congenital mental health and cognitive
             impairment disorder (e.g. mental retardation, cerebral palsy and other)

          -  History of acquired brain injury, mental health and cognitive impairment before
             starting cART

          -  HIV RNA &gt;1000 copies/mL within the past 6 months

          -  Any AIDS-defining illness or acute illness (e.g. fever, lowered consciousness,
             dehydration) at time of inclusion

          -  Children with parent(s) or caregiver(s) not wanting or not able to give informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grace Kinabo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kilimanjaro Christian Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andr√© van der Ven, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Van de Wijer, MD</last_name>
    <phone>+31638482007</phone>
    <email>L.vandewijer@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deborah Mchaile, MD</last_name>
    <phone>+255 755 284 464</phone>
    <email>deborahsia@hotmail.co.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kilimanjaro Christian Medical Centre</name>
      <address>
        <city>Moshi</city>
        <state>Kilimanjaro region</state>
        <zip>3010</zip>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Kinabo, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mawenzi Regional Hospital</name>
      <address>
        <city>Moshi</city>
        <state>Kilimanjaro region</state>
        <zip>3054</zip>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Tanzania</country>
  </location_countries>
  <reference>
    <citation>Van de Wijer L, Schellekens AFA, Burger DM, Homberg JR, de Mast Q, van der Ven AJAM. Rethinking the risk-benefit ratio of efavirenz in HIV-infected children. Lancet Infect Dis. 2016 May;16(5):e76-e81. doi: 10.1016/S1473-3099(16)00117-1. Epub 2016 Apr 18. Review.</citation>
    <PMID>27599655</PMID>
  </reference>
  <reference>
    <citation>Mothapo KM, Schellekens A, van Crevel R, Keuter M, Grintjes-Huisman K, Koopmans P, van der Ven A. Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment. CNS Neurol Disord Drug Targets. 2015;14(6):811-8.</citation>
    <PMID>25808896</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efavirenz</keyword>
  <keyword>Child Behavior</keyword>
  <keyword>Cognition</keyword>
  <keyword>Medication Adherence</keyword>
  <keyword>Drug-Related Side Effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurobehavioral Manifestations</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

